

Asterios Karagiannis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7907553/publications.pdf>

Version: 2024-02-01

114
papers

2,562
citations

304368

22
h-index

214527

47
g-index

114
all docs

114
docs citations

114
times ranked

3898
citing authors

#	ARTICLE	IF	CITATIONS
1	Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options. <i>Current Vascular Pharmacology</i> , 2022, 20, 52-61.	0.8	2
2	Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. <i>Hormones</i> , 2022, 21, 91-101.	0.9	8
3	Colchicine for the prevention of COVID-19 outcomes: All that glitters is not gold. <i>European Journal of Internal Medicine</i> , 2022, 97, 108-109.	1.0	0
4	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. <i>American Journal of Cardiology</i> , 2022, 167, 165-167.	0.7	1
5	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. <i>Kardiologia Polska</i> , 2022, 80, 80-82.	0.3	0
6	Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2022, 37, 170-174.	1.3	2
7	Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both? <i>European Journal of Internal Medicine</i> , 2022, 98, 125-127.	1.0	1
8	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. <i>Kardiologia Polska</i> , 2022, 80, 696-698.	0.3	1
9	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease. <i>American Journal of Cardiology</i> , 2022, 174, 188-189.	0.7	1
10	Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. <i>Vascular Medicine</i> , 2022, 27, 433-439.	0.8	8
11	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. <i>Hypertension Research</i> , 2021, 44, 179-187.	1.5	17
12	Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1165-1172.	1.4	5
13	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. <i>Microcirculation</i> , 2021, 28, e12665.	1.0	12
14	Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Hypertension</i> , 2021, 34, 404-413.	1.0	7
15	MO642DAPAGLIFLOZIN HAS NO IMPACT ON SHORT-TERM BLOOD PRESSURE VARIABILITY IN PATIENTS WITH TYPE-2 DIABETES MELLITUS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
16	Ertugliflozin + metformin as a treatment option for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2105-2111.	0.9	1
17	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. <i>Clinical Rheumatology</i> , 2021, 40, 4957-4968.	1.0	12
18	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. <i>Clinical Rheumatology</i> , 2021, 40, 4671-4674.	1.0	21

#	ARTICLE	IF	CITATIONS
19	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2021, 159, 143-146.	0.7	5
20	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of Hypertension, 2021, 39, 749-758.	0.3	38
21	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. American Journal of Cardiology, 2021, 161, 118-120.	0.7	2
22	Renovascular Hypertension: Novel Insights. Current Hypertension Reviews, 2020, 16, 24-29.	0.5	13
23	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e390-e400.	1.8	29
24	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. Digestive and Liver Disease, 2020, 52, 239-240.	0.4	1
25	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. Journal of Human Hypertension, 2020, 34, 764-767.	1.0	25
26	Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study. Rheumatology International, 2020, 40, 1997-2004.	1.5	8
27	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD. Journal of Clinical Hypertension, 2020, 22, 2239-2249.	1.0	4
28	SO036 THE EFFECT OF DAPAGLIFLOZIN ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
29	P0156 SHORT-TERM BLOOD PRESSURE VARIABILITY IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD STAGE 2, 3A, 3B AND 4. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
30	P0763 A COMPARATIVE STUDY OF ARTERIAL STIFFNESS AND WAVE REFLECTIONS IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
31	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. Journal of Clinical Hypertension, 2020, 22, 562-571.	1.0	24
32	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
33	Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. Journal of Nephrology, 2020, 33, 1289-1300.	0.9	7
34	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry, 2020, 27, 6682-6702.	1.2	16
35	Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. Kidney and Blood Pressure Research, 2019, 44, 679-689.	0.9	11
36	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry, 2019, 11, 1285-1303.	1.1	15

#	ARTICLE	IF	CITATIONS
37	FP516THE RENOPROTECTIVE EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
38	Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke. <i>International Journal of Hypertension</i> , 2019, 2019, 1-9.	0.5	6
39	Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1686-1694.	1.1	6
40	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. <i>Journal of Sexual Medicine</i> , 2019, 16, 1199-1211.	0.3	5
41	Insomnia and hypertension: A misty landscape. <i>Journal of Clinical Hypertension</i> , 2019, 21, 835-837.	1.0	3
42	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107927.	1.1	16
43	Determinants of pulse wave velocity index and potential implementations. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1493-1495.	1.0	1
44	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 253.	1.6	18
45	Multimodal Treatment of Homozygous Familial Hypercholesterolemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 3616-3621.	0.9	5
46	Arterial adaptations in athletes of dynamic and static sports disciplines – a pilot study. <i>Clinical Physiology and Functional Imaging</i> , 2019, 39, 183-191.	0.5	6
47	Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia. <i>Current Pharmaceutical Design</i> , 2019, 24, 5542-5547.	0.9	1
48	Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?. <i>Current Vascular Pharmacology</i> , 2019, 18, 38-42.	0.8	9
49	Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay. <i>Angiology</i> , 2018, 69, 745-748.	0.8	4
50	Subclinical target organ damage in primary aldosteronism. <i>Journal of Hypertension</i> , 2018, 36, 701.	0.3	2
51	Diabetes and lipid metabolism. <i>Hormones</i> , 2018, 17, 61-67.	0.9	192
52	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 634-636.	1.0	2
53	Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. <i>Maturitas</i> , 2018, 108, 45-52.	1.0	23
54	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. <i>Hormones</i> , 2018, 17, 83-95.	0.9	3

#	ARTICLE	IF	CITATIONS
55	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 942-948.	1.0	10
56	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	1.5	144
57	Antihypertensive therapy in acute ischemic stroke: where do we stand?. <i>Journal of Human Hypertension</i> , 2018, 32, 799-807.	1.0	7
58	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , 2018, 16, 130-142.	0.8	54
59	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2018, 16, 214-218.	0.8	13
60	Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. <i>Current Vascular Pharmacology</i> , 2018, 16, 219-227.	0.8	87
61	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2018, 16, 246-253.	0.8	69
62	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , 2018, 16, 276-288.	0.8	4
63	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. <i>Current Vascular Pharmacology</i> , 2018, 16, 393-400.	0.8	9
64	Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2018, 18, 139-146.	0.2	16
65	Acute Coronary Syndrome in Patients With Inflammatory Bowel Diseases: The Plaque and the Thrombus. <i>Angiology</i> , 2017, 68, 843-844.	0.8	3
66	Semaglutide, lipid-lowering drugs, and NAFLD. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 329-330.	5.5	14
67	Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. <i>Curr Med Res Opin</i> 2017;33:797-801. <i>Current Medical Research and Opinion</i> , 2017, 33, 2261-2262.	0.9	0
68	Blood pressure and cardiovascular outcomes: a closer look. <i>Lancet</i> , 2017, 389, 1295-1296.	6.3	1
69	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1251-1261.	1.3	9
70	Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 742-750.	1.1	8
71	Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et Al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. <i>J Clin Lipidol</i> . 2016;10(5):1091-1097. <i>Journal of Clinical Lipidology</i> , 2017, 11, 306-307.	0.6	0
72	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. <i>Current Pharmaceutical Design</i> , 2017, 23, 1510-1521.	0.9	15

#	ARTICLE	IF	CITATIONS
73	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. <i>Current Pharmaceutical Design</i> , 2017, 23, 1477-1483.	0.9	6
74	Off target effects of statins shape total mortality?. <i>Journal of Drug Assessment</i> , 2016, 5, 4-5.	1.1	1
75	Fitness: The "Secret" of Vascular Youth. <i>Journal of Clinical Hypertension</i> , 2016, 18, 290-291.	1.0	0
76	PATHWAY-2: spironolactone for resistant hypertension. <i>Lancet</i> , The, 2016, 387, 1371-1372.	6.3	0
77	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 241-242.	1.8	10
78	Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2016, 10, 64-68.	0.6	6
79	Medical students'™ satisfaction with the Applied Basic Clinical Seminar with Scenarios for Students, a novel simulation-based learning method in Greece. <i>Journal of Educational Evaluation for Health Professions</i> , 2016, 13, 13.	5.9	11
80	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. <i>Clinical Lipidology</i> , 2016, 11, 2-5.	0.4	3
81	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
82	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 7860.	1.4	130
83	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1215-1223.	1.5	68
84	Cardiovascular Risk in Middle East Populations. <i>Angiology</i> , 2015, 66, 801-802.	0.8	0
85	Arterial Stiffness and Emerging Biomarkers. <i>Angiology</i> , 2015, 66, 901-903.	0.8	12
86	Contrast-Induced Nephropathy. <i>Angiology</i> , 2015, 66, 508-513.	0.8	96
87	Health Benefits of the Mediterranean Diet. <i>Angiology</i> , 2015, 66, 304-318.	0.8	117
88	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 142-145.	1.2	15
89	Is There an Association Between Inflammatory Bowel Diseases and Carotid Intima-media Thickness? Preliminary Data. <i>Angiology</i> , 2014, 65, 543-550.	0.8	30
90	Subclinical Cushing's syndrome and cardiovascular disease. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 361.	5.5	8

#	ARTICLE	IF	CITATIONS
91	Peripheral artery disease in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2014, 28, 912.	1.2	3
92	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2014, 8, 936-944.	0.6	20
93	Are Patients With Inflammatory Bowel Diseases at Increased Risk for Cardiovascular Disease?. Clinical Gastroenterology and Hepatology, 2014, 12, 2134-2135.	2.4	6
94	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. Lancet Diabetes and Endocrinology, the, 2014, 2, 362-363.	5.5	13
95	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. Journal of the American Society of Hypertension, 2014, 8, 74-82.	2.3	75
96	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovascular Medicine Journal, 2014, 8, 55-60.	0.6	18
97	Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. Journal of Drug Assessment, 2013, 2, 67-71.	1.1	9
98	Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review. Diseases (Basel, Switzerland), 2013, 1, 51-72.	1.0	0
99	Treatment of primary aldosteronism: Where are we now?. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 15-20.	2.6	12
100	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. Current Vascular Pharmacology, 2010, 8, 792-803.	0.8	13
101	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. Neurological Research, 2010, 32, 326-331.	0.6	26
102	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. Open Cardiovascular Medicine Journal, 2009, 3, 26-34.	0.6	16
103	Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion on Pharmacotherapy, 2008, 9, 509-515.	0.9	115
104	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocrine-Related Cancer, 2008, 15, 693-700.	1.6	24
105	Atenolol: Differences in Mode of Action Compared with other Antihypertensives. An Opportunity to Identify Features that Influence Outcome?. Current Pharmaceutical Design, 2007, 13, 229-239.	0.9	11
106	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets, 2007, 11, 191-205.	1.5	24
107	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. Circulation Journal, 2007, 71, 1120-1127.	0.7	119
108	Pheochromocytoma: an update on genetics and management. Endocrine-Related Cancer, 2007, 14, 935-956.	1.6	114

#	ARTICLE	IF	CITATIONS
109	Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic Journal of Cardiology, 2006, 47, 298-307.	0.4	1
110	The Unilateral Measurement of Blood Pressure May Mask the Diagnosis or Delay the Effective Treatment of Hypertension. Angiology, 2005, 56, 565-569.	0.8	22
111	Gonadal dysfunction in systemic diseases. European Journal of Endocrinology, 2005, 152, 501-513.	1.9	187
112	Lack of an Association between Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Ischaemic Stroke. European Neurology, 2004, 51, 148-152.	0.6	21
113	Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease. Vascular Medicine, 2004, 9, 189-192.	0.8	6
114	Effects of Fosinopril on Renal Function in Patients with Mild to Moderate Essential Hypertension. Clinical Drug Investigation, 1996, 12, 251-258.	1.1	2